What Does Eli Lilly Offer That Merck Does Not?
Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?
Merck (MRK) and Eli Lilly (LLY) are both owned for a few best-selling medicines. Merck’s KEYTRUDA cancer drugs sold $8.6 billion in the third quarter of 2026. Lilly’s Mounjaro and Zepbound sold more than $16 billion together. Merck says KEYTRUDA nears peak sales in some of its uses. Lilly says drugs like Mounjaro and Zepbound still reach only about 1 in 10 patients in the U.S. So what did each company tell investors about its sales in 2026 and beyond?

Lilly Raised Its Sales Forecast Far More Than Merck
On October 29, 2026, Lilly raised its 2026 revenue forecast to a midpoint of $91.5 billion. In August, it had been $86 billion. Management pointed to fast uptake of the Medicare GLP-1 bridge program, which opened obesity drugs to more U.S. seniors. It also cited strong Mounjaro sales abroad. Lilly’s forecast for adjusted earnings per share slipped, though, to $35.50 at the midpoint from $36.00. Management said that forecast absorbs $4.57 per share of charges for drug programs Lilly bought in the third quarter.
Merck also raised its 2026 sales forecast, but only to a midpoint of $67.1 billion from $66.8 billion. The company lifted its adjusted earnings per share forecast to a midpoint of $2.80 from $2.71. The bigger news was about 2027. Management expects moderate sales growth that year. Generic copies of BRIDION, Januvia and Adempas are expected to cost it more than $2 billion of sales. So Lilly’s news centered on rising demand, while Merck’s focused on older drugs fading.
Merck stands to lose more than $2 billion of sales to generic copies in 2027. If you own Merck for the cash it pays you each year, that income rests on one drugmaker. The Trefis Income Solution pays a dividend yield about 3 times the S&P 500’s, from 50 companies that have paid dividends for at least 10 years in a row. See what it pays.
Lilly Pours Cash Into Factories, Merck Pays Holders
Compared with Merck, Lilly turns far less of its cash into free cash flow, the cash left after spending on plants and equipment. Over the twelve months to September 30, 2026, Lilly generated $30.6 billion of cash from operations but kept $11.7 billion of free cash flow. In the third quarter, Lilly also broke ground on a $6.5 billion plant in Houston and a $5 billion plant in Richmond, Virginia.
Merck kept $14.7 billion of free cash flow from $18.7 billion of operating cash over the same twelve months. Merck’s costs are set to rise, though. Management expects underlying operating expenses to grow at a mid to high single digit rate in 2027. For now, Merck hands far more cash to holders. At the November 19, 2026 close, a $10,000 stake in Merck carried about $260 a year in dividends, against about $50 for Lilly.
Merck’s Cheaper Price On Sales Versus Lilly’s Faster Growth
Over the twelve months to September 30, 2026, Lilly’s revenue grew 45.5%, against 4.9% for Merck. Lilly’s growth averaged 39.4% across the last three twelve-month periods, against 4.4% for Merck. Those three periods end on September 30 of 2024, 2025 and 2026.
Lilly also kept 51.3% of its revenue as operating income over those twelve months, against 9.2% at Merck. Merck’s figure includes operating losses in the first two quarters of 2026. Even Merck’s third-quarter operating margin of 31.9% trailed Lilly’s 53.7%. On net profit, that quarter went the other way: Merck’s net margin was 28.0%, against 26.4% for Lilly.
Lilly also carries a lighter debt load relative to its size. Merck’s total debt equals 16.4% of its market value, against 4.1% for Lilly.
Merck is the cheaper stock on sales, trading at 4.9 times sales against 13.9 times for Lilly. On earnings, the order flips: Merck trades at 133.6 times earnings, against 43.7 for Lilly. Merck’s multiple is high because its twelve-month profit includes the early-2026 losses.
On most of these measures, the evidence favors Lilly. Lilly has faster growth, a wider operating margin and a smaller debt load. Merck’s edges are a lower price on sales, more cash handed to holders, and an earnings forecast that went up while Lilly’s slipped. Both companies are expected to report in February 2027. Merck said customers’ purchase timing added about $550 million to its third-quarter sales. It expects part of that boost to reverse in the fourth quarter. Merck’s February report will show how much of its third-quarter operating margin holds up.
Some investors will pay up for Lilly’s growth, while others will take Merck’s cash. We have settled on our own way of making choices like this one, and we are always glad to hear a better one.
Found A Better Strategy? We’d Love To Learn.
Ours is the Trefis High Quality (HQ) Portfolio: 30 quality stocks in equal weight. Since its September 2020 launch it has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000. If yours has done better, tell us about it. If not, come take a look.
Spot an error or want more like this? Tell us in 10 seconds.